Welireg™ (belzutifan) Is Available From Onco360!

WELIREG™ (belzutifan) is a hypoxia-inducible factor inhibitor indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

Dosage and Administration1

The recommended dose for WELIREG is 120 mg (40 mg tablet x 3) orally once daily.

Dosage Forms and Strengths

WELIREG is available in 40 mg tablets (NDC 0006-5331-01) in 90 count pill bottles.
For full prescribing details visit: Welireg

How to Order


Call 877-662-6633.


Download the Oral Rx
Oncology Order Form and
fax it to 877-662-6355.
Oral Order Form


e-Prescribe to Onco360 in Louisville, KY 40223, or NPI# 1437577988 under the retail tab in your EMR/EHR or standalone e-prescribing application.

 1WELIREG prescribing information: Merck & Co., Inc. Accessed 7.21. WELIREG © copyright 2021 Merck Sharp & Dohme Corp., a subsidary of Merck & Co., Inc. All rights reserved